Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | PDE8B | O95263 | 7/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31586146 | 0.85 | PDE8B (0.40) | CYP4F2CYP4A11PDE8BATRGAA | |
| SCHEMBL21986747 | 0.81 | PDE8B (0.38) | CYP4F2CYP4A11PDE8BATRRXRA | |
| SCHEMBL21986774 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11PDE8BATRRXRA | |
| SCHEMBL21986776 | 0.81 | CYP4F2 (0.37) | CYP4F2CYP4A11PDE8BATRRXRA | |
| SCHEMBL31585878 | 0.81 | CYP4F2 (0.36) | CYP4F2CYP4A11PDE8BCYP2C19ATR | |
| SCHEMBL21986732 | 0.79 | CYP4F2 (0.38) | CYP4F2CYP4A11PDE8BATRRXRA | |
| SCHEMBL31585865 | 0.77 | RET (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL24373243 | 0.77 | GAA (0.41) | CYP4F2CYP4A11CYP2C19ATRRXRA | |
| SCHEMBL19637212 | 0.77 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL21050642 | 0.77 | CYP2C19 (0.51) | CYP4F2CYP4A11CYP2C19ATRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407765-B2 | Tetracyclic heteroaryl compounds | ASTRAZENECA, AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| EP-3790884-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | Astrazeneca AB (SE) | 2021-03-17 | — | — | EP | disclosed |
| CN-112074520-A | Tetracycloheteroaryl compounds | 阿斯利康(瑞典)有限公司 | 2020-12-11 | — | — | CN | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | CCNI, MCL1, MKI67 | CYP4F2 60/4885CYP4A11 112/4885PDE8B 2932/4885 |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | CCNI, MCL1, MKI67 | CYP4F2 60/4885CYP4A11 112/4885PDE8B 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.